Prof. Dr. Michael Johannes Pils

Michael advises on the employment law issues of company purchases as well as post-merger integration. He specialises in tailor-made advice for the structure of remuneration systems, questions of employment protection, data protection and health protection as well as company pensions. Michael has considerable experience with the employment law advice of Japanese, Chinese and US American companies. In addition, he advises on all questions of individual and collective employment law.

Since 2019 Michael is member of the executive board of the German-Japanese Society for Labour Law (Deutsch-Japanische Gesellschaft für Arbeitsrecht).

CV

Since 2020 Partner, Taylor Wessing

2010 - 2020 Salary Partner, Taylor Wessing

2012 Lecturer, University of Konstanz

Career

Since 2020 Partner, Taylor Wessing

2010 - 2020 Salary Partner, Taylor Wessing

2012 Lecturer, University of Konstanz

Education

2010 Established as a lawyer, Düsseldorf

2009 Second state examination, Düsseldorf

2009 Scholarship for the Post-Doc Programme DAAD, Oxford

Publications

Lieferkettensorgfaltspflichtengesetz, in: comply, 10/2021, gemeinsam mit Sebastian Rünz und Katja Schiffelholz Semedo

EU and Japan – A New Era of Free Trade, PlugIn – Wir denken das Recht der digitalen Zukunft, Ausgabe #12, August/2018

„Mitbestimmung im digitalen Betrieb“, in: „Digitalisierung der Arbeitswelt in Deutschland und Japan: Herausforderungen für das Arbeitsrecht“ (2018), herausgegeben von Franz J. Düwell, Karsten Haase, Martin Wolmerath. Delgany Publishing

Additional languages

Awards

The Best Lawyers™ in Germany 2025

Featured

Legal 500 2025

The Best Lawyers™ in Germany 2024

Legal 500 Germany 2024

Experience

Formycon

Under the leadership of the Frankfurt-based Taylor-Wessing partners Lars-Gerrit Lüßmann and Michael Sinhart, Formycon AG and ATHOS KG are merging their development activities in the field of so-called biosimilars, the follow-up products of biological medicines (biologics), in a long-term strategic partnership. The centrepiece of this agreement is Formycon AG’s participation in the rights of two biosimilars. The volume of the legally complex transaction (aggregate counter-performance) adds up to approximately 650 million euros.

Press release

Dr. Sebastian Beyer, LL.M. (Auckland)

Tobias Kraut

Felipe Villena

Clemens Niedner

Prof. Dr. Michael Johannes Pils

Marcus Hartmann